Regulatory Requirements
Regulatory expectations are converging across FDA, EMA, MHRA, and ICH. USDM helps life sciences teams translate 21 CFR Part 11, CSA, Annex 11, UDI/EU MDR, data integrity, privacy/security, and AI oversight into a controlled operating model that is inspection-ready, scalable, and defensible.
Global regulatory pressure
Modern programs have to satisfy more than one rulebook at once. FDA, EMA, MHRA, and ICH expectations now intersect across electronic records, software assurance, data integrity, cybersecurity, and AI-enabled workflows. USDM helps teams build one operating model instead of a stack of disconnected compliance projects.
Electronic records and signatures
Electronic records, e-signatures, access control, audit trails, and documented procedures still sit at the center of regulated digital work. USDM helps map those controls so systems stay trustworthy as platforms, vendors, and release cycles change.
CSA / CSV / lifecycle control
Validation is no longer a one-time paperwork event. USDM helps teams choose the right evidence, match testing to risk, and keep assurance current across cloud releases, configuration changes, and AI-enabled workflows.
Trustworthy data
ALCOA+ data integrity, privacy obligations, access governance, and cybersecurity controls now live in the same conversation. The goal is to keep records accurate, traceable, and usable when regulators, quality teams, or investigators need evidence.
AI and connected workflows
AI guidance is moving from theory to operating expectation. Whether the use case is drafting, decision support, or embedded product capability, leaders need intended use, human oversight, change control, vendor visibility, and traceable evidence.
What USDM does
USDM connects requirements mapping, control design, validation strategy, evidence architecture, and stakeholder alignment so compliance strengthens speed instead of slowing it down. The result is a pathway that lets the organization move without guessing at the regulatory edge cases.
Deep dives
Explore detailed briefs on high-priority regulatory, compliance, and AI topics — each connecting USDM expertise to the specific challenges your organization faces.
Learn how to achieve 21 CFR Part 11 compliance with secure electronic records, audit trails, eSignatures, and validation best practices for life sciences.
Read nowLearn what Computer Software Assurance (CSA) means for life sciences, how it differs from traditional validation, and how to apply a risk-based FDA-aligned approach.
Read nowExplore computer system validation services, understand CSV vs CSA, and learn how life sciences companies can modernize validation to improve compliance, speed, and scalability.
Read nowLearn how to improve EU MDR/IVDR EUDAMED readiness with practical steps for data, registration, governance, and global medical device regulatory alignment.
Read nowFrequently Asked Questions
Converging frameworks affect overlapping systems, data structures, validation methods, quality processes, and governance models. Updating SOPs alone is not enough; organizations need a coordinated strategy that redesigns processes, platforms, controls, and operating models together.
Several major frameworks are converging at the same time: ICH E6(R3), FDA direction around AI and lifecycle oversight, EU AI Act expectations, CSA, 21 CFR Part 11, and UDI/EU MDR. Together, they demand connected transformation rather than fragmented remediation.
CSA shifts validation from documentation volume toward evidence of system performance, intended use, critical thinking, and quality outcomes. It makes validation more efficient, scalable, and aligned with fast-moving technology environments.
Part 11 remains foundational because regulated digital transformation depends on trustworthy electronic records, secure electronic signatures, controlled access, and complete audit trails. It becomes part of the transformation architecture, not a legacy checklist.
Both affect regulated data, system controls, traceability, and oversight. Since they touch shared processes and platforms, organizations should address medical device regulatory readiness and AI governance through one coordinated operating model.
They need a unified operating model that connects Part 11, CSV/CSA, AI governance, and UDI/EU MDR readiness with regulatory expertise, GxP validation depth, platform understanding, and operating model design.
The strongest approach combines validated systems, risk-based assurance, automation, traceability, and regulatory readiness so organizations can reduce gaps, improve inspection readiness, and support scalable digital transformation.
CSA is the FDA’s risk-based framework for assuring that software used in production and quality systems performs as intended. It shifts attention from heavy documentation to critical thinking, intended use, and the level of assurance that matches patient safety, product quality, and process risk.
CSV emphasizes documented evidence that a system performs as intended in a compliant state, while CSA emphasizes risk-based assurance, unscripted testing where appropriate, and more efficient evidence for lower-risk functions. The goal is smarter validation, not lighter validation.
Computer system validation services help regulated organizations ensure systems consistently perform as intended, protect data integrity, and meet applicable compliance requirements. They typically include validation planning, risk assessment, traceability, testing, documentation, change control support, vendor oversight, and ongoing compliance monitoring.
Teams should confirm they have a validated and governed source of truth for UDI-related product data, can distinguish which devices must be registered now versus later, understand how device or label changes affect obligations, and have tools and teams that can support ongoing maintenance after the initial submission wave.
Talk to a regulatory specialist
USDM consultants work inside GxP environments every day. We help regulated organizations satisfy FDA, EMA, and global regulatory requirements without proportional increases in headcount.
